Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03950739 · ClinicalTrials.gov registry record · Phase 1
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
A Phase 1 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT03950739 is a Phase 1 study that has completed, run by United Therapeutics. The registered enrollment target is 51 participants.
The verdict
NCT03950739, a Phase 1 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
Interventions
- DRUG Treprostinil Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-09-17 |
| Est. Completion | 2023-08-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03950739
The ClinicalTrials.gov registry entry for NCT03950739 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treprostinil Inhalation Powder is the first listed.
NCT03950739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03950739 about?
NCT03950739 is a clinical study titled "Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso". This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
What is the current status of trial NCT03950739?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2019-09-17. Estimated completion is 2023-08-22.
What interventions are being tested in trial NCT03950739?
The interventions under investigation include: Treprostinil Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT03950739?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.